Thursday, June 11, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 58 of 1,261
  1. US 12239692

    Adeno-associated virus factor VIII vectors

    BIOMARIN PHARMACEUTICAL INC. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  2. US 12239712

    Combination therapy for the treatment of liver disease

    GALMED RESEARCH AND DEVELOPMENT LTD · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  3. US 12239729

    TRPV3 agonists for the treatment of skin conditions

    Soricimed Biopharma Inc. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  4. US 12241902

    Probes for detection of copper

    The Regents of the University of California · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  5. US 12241099

    Peptide therapeutics for treating Alzheimer's disease and related conditions

    The Board of Regents of the University of Oklahoma · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  6. US 12241087

    Compositions and methods for differentiating stem cells into NK cells

    CRISPR THERAPEUTICS AG · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  7. US 12241064

    REVERSIR™ compounds

    Alnylam Pharmaceuticals, Inc. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  8. US 12240914

    Antibody against factor XIa in activated form of coagulant factor XI, preparation method therefor and use thereof

    MAB-LEGEND BIOTECH CO., LTD. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  9. US 12240908

    N-terminal scFv multispecific binding molecules

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  10. US 12240907

    N-terminal scFv multispecific binding molecules

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  11. US 12240833

    Pyridazinone compounds and uses thereof

    EDGEWISE THERAPEUTICS, INC. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  12. US 12240918

    Bispecific antibodies against plasma kallikrein and factor XII

    Takeda Pharmaceutical Company Limited · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  13. US 12239694

    Methods and compositions for improved cognition

    The Regents of the University of California · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  14. US 12241067

    Compounds and methods for reducing LRRK2 expression

    Ionis Pharmaceuticals, Inc. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  15. US 12239709

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  16. US 12240816

    Deuterated compounds and uses thereof

    Aldeyra Therapeutics, Inc. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  17. US 12240831

    Pyridazinone compounds and uses thereof

    EDGEWISE THERAPEUTICS, INC. · Granted Mar 4, 2025 · Expires Feb 27, 2045

    granted
  18. US 2025064917

    HVT AIV VECTORS AND USES THEREOF

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Feb 27, 2025 · Expires Feb 22, 2045

    granted
  19. US 2025064788

    TREATMENT OF MIGRAINE

    ALLERGAN PHARMACEUTICALS INT LTD [IE] · Granted Feb 27, 2025 · Expires Feb 22, 2045

    granted
  20. WO 2025040080

    TRAITEMENT DU CANCER DE L'OESOPHAGE PAR ANTI-LAG3, ANTI-PD-1 ET CHIMIOTHÉRAPIE

    BEIGENE SWITZERLAND GMBH [CH] · Granted Feb 27, 2025 · Expires Feb 22, 2045

    granted
  21. WO 2025041076

    COMPOSÉS BICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE CDK

    BEIGENE SWITZERLAND GMBH [CH] · Granted Feb 27, 2025 · Expires Feb 22, 2045

    granted
  22. WO 2025043148

    INHIBITEURS DE PROTÉINE DE LIAISON À L'ÉMOPAMIL ET LEURS UTILISATIONS

    BIOGEN MA INC [US] · Granted Feb 27, 2025 · Expires Feb 22, 2045

    granted
  23. US 12234460

    Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 25, 2025 · Expires Feb 20, 2045

    granted
  24. US 12234461

    Targeted non-viral DNA insertions

    THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION · Granted Feb 25, 2025 · Expires Feb 20, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.